CTC Alternative Strategies Ltd. Makes New Investment in Johnson & Johnson $JNJ

Key Points

• CTC Alternative Strategies Ltd. has acquired a new stake in Johnson & Johnson, purchasing 2,800 shares valued at approximately $464,000.
• Institutional investors currently own 69.55% of Johnson & Johnson's stock, with recent increases in positions from various hedge funds during the first quarter.
• Johnson & Johnson has declared a quarterly dividend of $1.30, representing an annualized yield of 2.9%, payable on September 9th to shareholders of record by August 26th.

CTC Alternative Strategies Ltd. acquired a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,800 shares of the company's stock, valued at approximately $464,000.

Other institutional investors have also modified their holdings of the company. Highline Wealth Partners LLC increased its holdings in shares of Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after acquiring an additional 86 shares during the period. Stone House Investment Management LLC acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at $47,000. 1248 Management LLC acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at $48,000. von Borstel & Associates Inc. acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at $52,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Barclays lifted their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Bank of America lifted their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a report on Thursday, July 17th. Citigroup lifted their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a report on Thursday, August 21st. Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Finally, Leerink Partners cut shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $176.29.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

JNJ traded down $0.13 during trading on Monday, hitting $178.30. The stock had a trading volume of 8,325,117 shares, compared to its average volume of 7,659,331. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The firm has a market capitalization of $429.40 billion, a P/E ratio of 19.07, a PEG ratio of 2.27 and a beta of 0.40. The company's 50-day moving average price is $169.09 and its 200 day moving average price is $160.90. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson's revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's payout ratio is presently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.